Compare Alexandria Real Estate Equities Inc (ARE) vs Biogen Inc (BIIB) Price & Performance

Alexandria Real Estate Equities (ARE) trades at $48.07, down 0.58% on the day, with a bearish technical signal and mixed earnings. The stock shows negative profitability metrics, including a net income margin of -37.12% and ROE of -6.29%, though it beat FFO estimates in Q2 2026. Recent news highlights leasing momentum and a narrowed full-year FFO guidance range, while a pending lawsuit adds uncertainty.

The outlook remains cautious due to weak earnings and high debt, but the stock trades below book value, offering potential value. Risks include ongoing losses, litigation, and real estate market volatility. Analyst consensus is mixed with a $53.71 price target, suggesting modest upside if operational improvements materialize.

Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.

Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.